Corren J, Katelaris CH, Castro M, et al. - In the phase 3 QUEST study, dupilumab 200 and 300 mg every 2 weeks was demonstrated as efficacious and safe relative to placebo in patients with uncontrolled, moderate-to-severe asthma. Researchers herein performed a post hoc analysis examining the effect of dupilumab on efficacy outcomes and asthma control across a range of historical exacerbation rates in patients with type 2−high asthma. Significant reduction in severe exacerbations and improvement in forced expiratory volume in 1 s and asthma control were noted in patients with raised type 2 biomarkers in correlation with receiving dupilumab; this was observed irrespective of exacerbation history and baseline ICS dose.